Literature DB >> 28256571

Environmental exposures as a risk factor for fibrolamellar carcinoma.

Rondell P Graham1, John R Craig2, Long Jin1, Andre M Oliveira1, John R Bergquist3, Mark J Truty3, Taofic Mounajjed1, Patricia T Greipp1, Michael S Torbenson1.   

Abstract

Fibrolamellar carcinoma was first described in 1956. Subsequent large studies failed to identify cases before 1939 (the start of the World War II). This finding, combined with the presence of aryl hydrocarbon receptors on the tumor cells, have suggested that fibrolamellar carcinomas may be caused by environmental exposures that are new since World War II. To investigate this possibility, the surgical pathology files before 1939 were reviewed for hepatocellular carcinomas resected in young individuals. Two cases of fibrolamellar carcinoma were identified, from 1915 to 1924. The diagnosis of fibrolamellar carcinoma was confirmed at the histologic, ultrastructural and proteomic levels. These two fibrolamellar carcinoma cases clarify a key aspect of fibrolamellar carcinoma biology, reducing the likelihood that these tumors result exclusively from post World War II environmental exposures.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28256571     DOI: 10.1038/modpathol.2017.7

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  38 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier.

Authors:  Zenichi Morise; Zenichi Morize; Atsushi Sugioka; Yoshikazu Mizoguchi; Junko Fujita; Sojun Hoshimoto; Takaumi Kato; Akitake Hasumi
Journal:  J Gastroenterol Hepatol       Date:  2005-07       Impact factor: 4.029

3.  Primary liver carcinoma arising in people younger than 30 years.

Authors:  Walter M Klein; Ernesto P Molmenti; Paul M Colombani; Davinder S Grover; Kathleen B Schwarz; John Boitnott; Michael S Torbenson
Journal:  Am J Clin Pathol       Date:  2005-10       Impact factor: 2.493

4.  Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.

Authors:  Rondell P Graham; Luigi M Terracciano; Alexander Meves; Patrick M Vanderboom; Surendra Dasari; Matthew M Yeh; Michael S Torbenson; Michael W Cruise
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

5.  Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users.

Authors:  Supriya Munshaw; Hyon S Hwang; Michael Torbenson; Jeffrey Quinn; Kasper D Hansen; Jacquie Astemborski; Shruti H Mehta; Stuart C Ray; David L Thomas; Ashwin Balagopal
Journal:  Hepatology       Date:  2012-07-06       Impact factor: 17.425

6.  Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.

Authors:  Stephen C Ward; Jiaoti Huang; Satish K Tickoo; Swan N Thung; Marc Ladanyi; David S Klimstra
Journal:  Mod Pathol       Date:  2010-05-21       Impact factor: 7.842

Review 7.  Fibrolamellar hepatocellular carcinoma.

Authors:  H G Kwee
Journal:  Am Fam Physician       Date:  1989-08       Impact factor: 3.292

8.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

Review 9.  The impact of translocations and gene fusions on cancer causation.

Authors:  Felix Mitelman; Bertil Johansson; Fredrik Mertens
Journal:  Nat Rev Cancer       Date:  2007-03-15       Impact factor: 60.716

Review 10.  Mouse models of liver cancer: Progress and recommendations.

Authors:  Li He; De-An Tian; Pei-Yuan Li; Xing-Xing He
Journal:  Oncotarget       Date:  2015-09-15
View more
  3 in total

1.  DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma.

Authors:  Edward R Kastenhuber; Gadi Lalazar; Shauna L Houlihan; Darjus F Tschaharganeh; Timour Baslan; Chi-Chao Chen; David Requena; Sha Tian; Benedikt Bosbach; John E Wilkinson; Sanford M Simon; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-21       Impact factor: 11.205

2.  Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.

Authors:  Adam B Francisco; Matt Kanke; Andrew P Massa; Timothy A Dinh; Ramja Sritharan; Khashayar Vakili; Nabeel Bardeesy; Praveen Sethupathy
Journal:  JCI Insight       Date:  2022-06-08

Review 3.  A Multidisciplinary Approach to the Management of Fibrolamellar Carcinoma: Current Perspectives and Future Prospects.

Authors:  Georgios Polychronidis; Anastasia Murtha-Lemekhova; Juri Fuchs; Evdokia Karathanasi; Katrin Hoffmann
Journal:  Onco Targets Ther       Date:  2022-10-03       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.